AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (trastuzumab ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

The study drug was compared to the chemotherapy Taxol combined with Perjeta and another Roche monoclonal antibody drug, Herceptin. This three-drug combination is a standard first-line treatment ...